COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN DOMINICAN REPUBLIC, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL

被引：0
|
作者：
Obando, C. A. [1 ]
Desanvicente-Celis, Z. [1 ]
Gonzalez, L. [2 ]
Muschett, D. [1 ]
Gonzalez, F. [1 ]
Goldberg, P. [1 ]
机构：
[1] Janssen, Panama City, Panama
[2] Janssen, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN121
引用
收藏
页码：A635 / A635
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN THE REPUBLIC OF PANAMA, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL
    Obando, C. A.
    Desanvicente-Celis, Z.
    Gonzalez, L.
    Muschett, D.
    Gonzalez, F.
    Goldberg, P.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [2] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN
    Shibahara, H.
    Shiroiwa, T.
    Nakamura, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A416
  • [3] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY
    Thompson, Melissa
    Li, Tracy
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian
    He, Jianming
    Saadi, Ryan
    JOURNAL OF UROLOGY, 2014, 191 (04): : E810 - E810
  • [4] COST-EFFECTIVENESS OF NIRAPARIB PLUS ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Duru, E.
    Mattingly, T. J.
    Malone, D. C.
    VALUE IN HEALTH, 2024, 27 (06) : S62 - S62
  • [5] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [6] Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Sternberg, C. N.
    Molina, A.
    North, S.
    Mainwaring, P.
    Fizazi, K.
    Hao, Y.
    Rothman, M.
    Gagnon, D. D.
    Kheoh, T.
    Haqq, C. M.
    Cleeland, C.
    de Bono, J. S.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1017 - 1025
  • [7] Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
    Rudakova, A. V.
    Meshkov, D. O.
    Mishugin, S. V.
    ONKOUROLOGIYA, 2014, 10 (03): : 73 - 77
  • [8] Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
    ten Ham, Renske M. T.
    van Nuland, Merel
    Vreman, Rick A.
    de Graaf, Laurens G.
    Rosing, Hilde
    Bergman, Andre M.
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    Hovels, Anke M.
    VALUE IN HEALTH, 2021, 24 (01) : 121 - 128
  • [9] An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy.
    Li, Tracy
    Thompson, Melissa
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian San
    He, Jianming
    Saadi, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE AND SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Gong, C. L.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A82 - A83
12345